September 29, 2020 • 12:00 PM - 4:10 PM ET


There has been a great deal of activity surrounding the 340B program this year. We’ve seen its core stakeholders reacting and anticipating the consequences of these changes, all the while, still in the midst of managing the impact of the pandemic and economic downturn that’s ensued. This day-long webinar series highlights the most pressing issues both 340B covered entities and manufacturers need to consider to develop appropriate strategies around their 340B program initiatives. Participate in one or all of the sessions of the day to stay abreast of the latest information, impacts, and recommendations for effective and compliant program participation.



Webinar Agenda:


12:00 – 1:00 pm

Threats and Opportunities in the 340B Program – Impact of Recent Business, Legislative, and Policy Developments
As we get closer to Election Day, the 340B program is back in the public eye, and under an intense microscope. An active year already, punctuated by the impact of the pandemic, stakeholders have seen significant action on 340B including the following –

  • a growing dispute between providers and manufacturers around contract pharmacy arrangements;
  • next steps in the dispute including possible legal and legislative action;
  • the federal appeals court ruling on Medicare Part B reimbursement and CMS’s efforts to decrease reimbursement rates further;
  • the Trump Administration’s Executive Orders on drug pricing, including pass-through of 340B discounts for insulin and EpiPens;
  • state actions to prohibit PBMs from discriminating against 340B entities and implications of recent court cases.

During this opening session of the 340B webinar series, examine where we are, how we got here, what to expect moving forward, and the potential threats and opportunities for various stakeholders involved in the 340B program.

  • Outline recent activity by key industry players, regulators, courts, and policymakers
  • Explore recent developments in state capitols impacting 340B stakeholders
  • Examine the upcoming Presidential and Congressional races and their impact on drug pricing and the 340B program
Ted Slafsky
Ted Slafsky
Publisher and CEO
340B Report
View Bio
Michael McCaughan
Michael McCaughan
Editor
The RPM Report
View Bio
Peggy Tighe
Peggy Tighe, JD
Principal
Powers Pyles Sutter & Verville PC
View Bio



1:00 – 2:00 pm

APEXUS ADDRESS: 340B Trends, Hot Topics, and Solutions Supporting Compliance
Apexus, the HRSA-designated Prime Vendor for the 340B Drug Pricing Program, leads a 340B update on trends in the current environment. Hear the hot topics that manufacturers and entities ask the national call center, Apexus Answers. Also, gain insights on new and updated tools that support compliance and learn about opportunities to partner with other stakeholders to address 340B challenges for positive outcomes.

  • Review 340B trends and hot topics
  • Discuss new and updated tools that support compliance
  • Share solutions that involve partnership among stakeholders and address 340B challenges
Mike Benedict
Mike Benedict
Vice President, Pharmacy Operations
Apexus
View Bio



2:10 – 3:10 pm

Drive 340B Program Integrity – The Importance of an Engaged 340B Oversight Committee and Internal Monitoring Data

A key component of the 340B program is program compliance and integrity.  Covered entities must agree to comply with all 340B statutes, policies, and guidance to maintain the integrity of its 340B program.  Hear how an engaged 340B Oversite Committee, along with the use of internal monitoring data can help a covered entity achieve this goal of program integrity through best practices and required elements.

  • Identify the key stakeholders of the 340B Oversight Committee and describe the expectations for each member and the committee
  • Examine the internal monitoring procedures that align with the HRSA’s required elements and best practices
  • Better understand how the Oversight Committee utilizes the internal monitoring data to drive program integrity
Jason Mills
Jason Mills, PharmD, ACE
Senior Consultant
Comprehensive Pharmacy Services
View Bio



3:10 – 4:10 pm

How CEs and Manufacturers Can Better Support Each Other to Ensure Partnerships of Mutual Benefit
In the current climate, where the relationships between CEs and Manufacturers may feel more strained than ever, it’s also more important than ever to find ways to increase collaboration, streamline communication, and better address each other’s needs – particularly in realm of data sharing. Gain insights from both the CE and manufacturer perspectives as we look at the realities – and the optics – to find common ground on requests and responses from each side to ensure program integrity and drive towards a more sustainable 340B Program, where the central focus remains on serving a vulnerable patient population.

Noreen A Palinkas
Noreen A Palinkas
Director, Pharmacy Compliance
Boston Medical Center
View Bio
Mujeeb Rafiuddin
Mujeeb Rafiuddin
340B National Account Manager
Genentech
View Bio



Contact



General Inquiries:

World Congress Customer Relations
Phone: 781-939-2400
Toll-free: 800-767-9499
Email: wcreg@worldcongress.com

Receive Email Updates

Be the first to learn about our upcoming events, promotions and news.